Europe To Review Blood Clot Risks In Contraceptives

Law360, New York (January 28, 2013, 7:19 PM EST) -- The European Medicines Agency on Monday announced that it will review the risks associated with third- and fourth-generation combined oral contraceptives, such as Yaz, after French regulators raised concerns that the drugs carry a higher risk of blood clots and should be restricted.

France asked for the review, the EMA said. France's health ministry announced this month that it would no longer reimburse third-generation contraceptive pills and asked doctors not to prescribe such pills unless a patient could not take earlier versions.

The EMA's Pharmacovigilance Risk...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.